Sign In
Buy KROS
$10.50
-0.0500 (-0.474%)
At Close: Jun 03, 2026
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
08:00am, Wednesday, 03'rd Jan 2024
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ
LEXINGTON, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
Keros Therapeutics to Present at Upcoming Healthcare Conferences
08:00am, Tuesday, 07'th Nov 2023
LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results
08:00am, Monday, 06'th Nov 2023
LEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
08:00am, Monday, 07'th Aug 2023
LEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
LEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors.
LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference
08:00am, Monday, 12'th Jun 2023
LEXINGTON, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics to Present at Goldman Sach's 44th Annual Global Healthcare Conference
08:00am, Wednesday, 07'th Jun 2023
LEXINGTON, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association
04:01pm, Thursday, 11'th May 2023
LEXINGTON, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia
Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know
01:42pm, Monday, 01'st May 2023
Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Keros Therapeutics: Undercovered Company With Data From All Programs
08:07am, Sunday, 30'th Apr 2023
KROS is a small company with three clinical programs. Surprisingly, each program has clinical data.
Why Shares of Keros Therapeutics Jumped This Week
01:55pm, Friday, 21'st Apr 2023
Keros is a pre-revenue biotech with two therapies in phase 2 trials. The company focuses on treatments for blood and musculoskeletal disorders.
Is a Surprise Coming for Keros Therapeutics (KROS) This Earnings Season?
09:47am, Thursday, 02'nd Mar 2023
Keros Therapeutics (KROS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Keros Therapeutics to Present at Cowen's 43rd Annual Health Care Conference
08:00am, Wednesday, 01'st Mar 2023
LEXINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc
